Cargando…

Ocular Adverse Events after Inactivated COVID-19 Vaccination

Purpose: To report the clinical characteristics of ocular adverse events that have occurred, in China, after vaccination with inactivated COVID-19 vaccines. Methods: A retrospective cross-sectional observational study was conducted of ocular disorders that occurred within 15 days from any dose of an...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zhihua, Hu, Feng, Li, Qian, Wang, Shuang, Chen, Chunli, Zhang, Yongpeng, Mao, Yu, Shi, Xuehui, Zhou, Haiying, Cao, Xusheng, Peng, Xiaoyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9230105/
https://www.ncbi.nlm.nih.gov/pubmed/35746527
http://dx.doi.org/10.3390/vaccines10060918
_version_ 1784734977900937216
author Li, Zhihua
Hu, Feng
Li, Qian
Wang, Shuang
Chen, Chunli
Zhang, Yongpeng
Mao, Yu
Shi, Xuehui
Zhou, Haiying
Cao, Xusheng
Peng, Xiaoyan
author_facet Li, Zhihua
Hu, Feng
Li, Qian
Wang, Shuang
Chen, Chunli
Zhang, Yongpeng
Mao, Yu
Shi, Xuehui
Zhou, Haiying
Cao, Xusheng
Peng, Xiaoyan
author_sort Li, Zhihua
collection PubMed
description Purpose: To report the clinical characteristics of ocular adverse events that have occurred, in China, after vaccination with inactivated COVID-19 vaccines. Methods: A retrospective cross-sectional observational study was conducted of ocular disorders that occurred within 15 days from any dose of an inactivated COVID-19 vaccine. Information on gender, age, the interval between the vaccination and ocular symptoms, laterality, duration of the ocular symptoms, primary visual acuity, and clinical diagnosis were retrospectively collected. Results: Twenty-four patients were involved in the study, including 15 females and 9 males, with a mean age of 41 ± 16 years (range of 8–71 years). The patients all denied a prior history of COVID-19 infection. Ocular adverse events occurred after the first dose of vaccine in 18 patients and, after the second or third doses, in six patients. The interval between vaccination with the inactivated COVID-19 vaccine and ocular symptoms was 6 ± 5 days; six patients were bilaterally involved and 18 patients were unilaterally involved. Regarding the diagnosis, 10 patients were diagnosed with white dot syndrome (WDS), 9 patients were diagnosed with uveitis, and 5 patients were diagnosed with retinal vascular disorders. The ages of patients with WDS were younger than those with uveitis or retinal vascular disorders (32 ± 10 vs. 48 ± 18, p < 0.05). For patients diagnosed with WDS, the best-corrected visual acuity (BCVA) was 0.74 ± 0.73 LogMAR. For patients diagnosed with retinal vascular disorders or uveitis, the BCVA was 1.44 ± 1.26 LogMAR. There was no significant difference (p > 0.05). Conclusions: A relationship cannot be established between inactivated COVID-19 vaccines and ocular disorders; therefore, further investigation of the clinical spectrum of ocular adverse events after vaccination with an inactivated COVID-19 vaccine is necessary.
format Online
Article
Text
id pubmed-9230105
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92301052022-06-25 Ocular Adverse Events after Inactivated COVID-19 Vaccination Li, Zhihua Hu, Feng Li, Qian Wang, Shuang Chen, Chunli Zhang, Yongpeng Mao, Yu Shi, Xuehui Zhou, Haiying Cao, Xusheng Peng, Xiaoyan Vaccines (Basel) Article Purpose: To report the clinical characteristics of ocular adverse events that have occurred, in China, after vaccination with inactivated COVID-19 vaccines. Methods: A retrospective cross-sectional observational study was conducted of ocular disorders that occurred within 15 days from any dose of an inactivated COVID-19 vaccine. Information on gender, age, the interval between the vaccination and ocular symptoms, laterality, duration of the ocular symptoms, primary visual acuity, and clinical diagnosis were retrospectively collected. Results: Twenty-four patients were involved in the study, including 15 females and 9 males, with a mean age of 41 ± 16 years (range of 8–71 years). The patients all denied a prior history of COVID-19 infection. Ocular adverse events occurred after the first dose of vaccine in 18 patients and, after the second or third doses, in six patients. The interval between vaccination with the inactivated COVID-19 vaccine and ocular symptoms was 6 ± 5 days; six patients were bilaterally involved and 18 patients were unilaterally involved. Regarding the diagnosis, 10 patients were diagnosed with white dot syndrome (WDS), 9 patients were diagnosed with uveitis, and 5 patients were diagnosed with retinal vascular disorders. The ages of patients with WDS were younger than those with uveitis or retinal vascular disorders (32 ± 10 vs. 48 ± 18, p < 0.05). For patients diagnosed with WDS, the best-corrected visual acuity (BCVA) was 0.74 ± 0.73 LogMAR. For patients diagnosed with retinal vascular disorders or uveitis, the BCVA was 1.44 ± 1.26 LogMAR. There was no significant difference (p > 0.05). Conclusions: A relationship cannot be established between inactivated COVID-19 vaccines and ocular disorders; therefore, further investigation of the clinical spectrum of ocular adverse events after vaccination with an inactivated COVID-19 vaccine is necessary. MDPI 2022-06-09 /pmc/articles/PMC9230105/ /pubmed/35746527 http://dx.doi.org/10.3390/vaccines10060918 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Li, Zhihua
Hu, Feng
Li, Qian
Wang, Shuang
Chen, Chunli
Zhang, Yongpeng
Mao, Yu
Shi, Xuehui
Zhou, Haiying
Cao, Xusheng
Peng, Xiaoyan
Ocular Adverse Events after Inactivated COVID-19 Vaccination
title Ocular Adverse Events after Inactivated COVID-19 Vaccination
title_full Ocular Adverse Events after Inactivated COVID-19 Vaccination
title_fullStr Ocular Adverse Events after Inactivated COVID-19 Vaccination
title_full_unstemmed Ocular Adverse Events after Inactivated COVID-19 Vaccination
title_short Ocular Adverse Events after Inactivated COVID-19 Vaccination
title_sort ocular adverse events after inactivated covid-19 vaccination
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9230105/
https://www.ncbi.nlm.nih.gov/pubmed/35746527
http://dx.doi.org/10.3390/vaccines10060918
work_keys_str_mv AT lizhihua ocularadverseeventsafterinactivatedcovid19vaccination
AT hufeng ocularadverseeventsafterinactivatedcovid19vaccination
AT liqian ocularadverseeventsafterinactivatedcovid19vaccination
AT wangshuang ocularadverseeventsafterinactivatedcovid19vaccination
AT chenchunli ocularadverseeventsafterinactivatedcovid19vaccination
AT zhangyongpeng ocularadverseeventsafterinactivatedcovid19vaccination
AT maoyu ocularadverseeventsafterinactivatedcovid19vaccination
AT shixuehui ocularadverseeventsafterinactivatedcovid19vaccination
AT zhouhaiying ocularadverseeventsafterinactivatedcovid19vaccination
AT caoxusheng ocularadverseeventsafterinactivatedcovid19vaccination
AT pengxiaoyan ocularadverseeventsafterinactivatedcovid19vaccination